Research Frontier | Retrospective Comparison of Transcutaneous Auricular Vagus Nerve Stimulation and Medication in Major Depressive Disorder

Introduction

For major depressive disorder (MDD), medication is not an option that every patient can tolerate or benefit from adequately. Transcutaneous auricular vagus nerve stimulation (taVNS) is being investigated as a nonpharmacological intervention, but whether it can improve core depressive symptoms when compared directly with a commonly used antidepressant requires cautious interpretation.
On October 22, 2026, Yu-Lin Wu and colleagues published an article online in BMC Psychiatry that retrospectively compared 8-week outcomes of taVNS and escitalopram, a selective serotonin reuptake inhibitor, for the treatment of MDD. After propensity score matching, each group included 120 patients.
The study's central finding was not that taVNS outperformed medication. The prespecified primary endpoint, change in Montgomery-Åsberg Depression Rating Scale (MADRS) score, did not differ significantly between groups. Between-group differences did emerge in sleep, cognition, anhedonia, and heart rate variability. These findings are better viewed as signals for subsequent trials than as an established efficacy advantage.

Study Background :Evidence Gap

In addition to persistent low mood, MDD is often accompanied by sleep disturbance, cognitive impairment, and anhedonia. Escitalopram primarily acts on the serotonergic system and is commonly used in clinical practice, but its onset of action takes time, and some patients experience adverse effects such as gastrointestinal discomfort, somnolence, and dry mouth. Cognitive impairment and anhedonia may not improve in parallel with core depressive symptoms.
taVNS uses an auricular electrode to stimulate the auricular branch of the vagus nerve and differs from both implanted vagus nerve stimulation and transcutaneous cervical vagus nerve stimulation. Its afferent signals may influence brain regions involved in mood, autonomic regulation, and arousal through the nucleus tractus solitarius (NTS). However, most previous evidence has come from sham-controlled trials or small studies. Direct comparisons of taVNS with standard medication in clinical populations with similar baseline characteristics remain limited.

Study Methods :Retrospective Cohort

The investigators reviewed patients treated at a single center in outpatient or inpatient settings from September 2021 to September 2025. Eligible patients were 18-65 years old, met the diagnostic criteria for MDD, had a baseline total score of at least 24 on the 17-item Hamilton Depression Rating Scale (HAMD-17), and had a MADRS total score greater than 35. Treatment was selected by the clinician based on patient preference, previous efficacy and tolerability, device availability, cost, and other factors rather than being randomly assigned.
The original cohort comprised 289 eligible patients: 152 in the escitalopram group and 137 in the taVNS group. The study used 1:1 nearest-neighbor propensity score matching with a caliper of 0.02, retaining 120 patients in each group. After matching, no significant differences were observed in measured variables such as age, sex, body mass index, educational attainment, duration of the current episode, recurrence status, and baseline symptom scores. Propensity scores can balance only variables that were recorded and entered into the model; they cannot eliminate unmeasured confounding or confounding by indication.
Escitalopram was started at 10 mg/day, adjusted within 1-2 weeks according to tolerability and clinical response, and maintained at 10-20 mg/day. taVNS was applied to the left cymba conchae at a frequency of 20 Hz and a pulse width of 200 μs. Current was adjusted to 1-5 mA according to each patient's sensory threshold. Sessions lasted 30 minutes and were given on 5 consecutive days followed by 2 rest days each week for 8 weeks. Neither group received other antidepressants, antipsychotics, or mood stabilizers during treatment.
The primary endpoint was the change in MADRS score from baseline to week 8. Other depression measures, the Hamilton Anxiety Rating Scale (HAMA), sleep, cognition, anhedonia, heart rate variability (HRV), and safety measures were designated exploratory outcomes. Continuous outcomes were analyzed primarily by analysis of covariance with the baseline value as a covariate, and adjusted between-group differences with 95% confidence intervals were reported. The P values for exploratory analyses were not adjusted for multiple comparisons. Neither patients nor outcome assessors were blinded, and the analysis included only patients who completed treatment and follow-up.

Study Results:Primary Outcome

At week 8, the changes in MADRS score from baseline were −22.72 ± 6.04 points in the escitalopram group and −22.26 ± 6.08 points in the taVNS group; the between-group comparison yielded P = 0.530. After adjustment for baseline, the between-group difference in week 8 MADRS score was 0.30 points (95% confidence interval, −1.07 to 1.67; P = 0.667). Clinical response rates were 65.83% and 63.33%, respectively (P = 0.686), and remission rates were 39.17% and 36.67%, respectively (P = 0.690).
The HAMD-17 findings were similar: changes were −18.64 ± 5.75 points and −18.51 ± 5.30 points in the two groups, respectively (P = 0.852), and the adjusted between-group difference at week 8 was 0.28 points (95% confidence interval, −0.91 to 1.47; P = 0.641). Anxiety scores decreased in both groups, but the between-group difference was not significant. Thus, the study did not find taVNS to be superior to escitalopram for core depressive or anxiety symptoms. Because this was not a noninferiority trial, the absence of a significant difference cannot be interpreted as equivalence or as evidence that taVNS is noninferior to medication.
Figure 1 Outcomes for Core Depressive Symptoms
The two tables show week 8 MADRS and HAMD-17 scores, changes from baseline, and MADRS-defined clinical response and remission rates. None of the key between-group comparisons reached statistical significance.

Exploratory Outcomes


For sleep, the adjusted between-group difference on the Pittsburgh Sleep Quality Index (PSQI) was −0.75 points (95% confidence interval, −0.83 to −0.66; P < 0.001), favoring taVNS. At week 8, 31.67% of patients in the taVNS group and 18.33% in the escitalopram group achieved good sleep (PSQI < 5; P = 0.017).

Figure 2 Anxiety and Sleep Outcomes
In the upper panel, green represents the escitalopram group and magenta represents the taVNS group. Anxiety scores decreased in both groups, but the between-group difference was not significant. The lower table shows an exploratory difference in sleep outcomes favoring taVNS.

The mean change from baseline on the Montreal Cognitive Assessment (MoCA) was −0.02 ± 3.46 points in the escitalopram group and 0.96 ± 3.31 points in the taVNS group. The adjusted between-group difference was 0.67 points (95% confidence interval, 0.09 to 1.26; P = 0.024). Changes on the Snaith-Hamilton Pleasure Scale (SHAPS) were −11.43 ± 7.97 and −13.44 ± 7.19 points, respectively, with an adjusted between-group difference of −1.37 points (95% confidence interval, −2.68 to −0.07; P = 0.040). Both results favored taVNS, but they were exploratory findings without adjustment for multiple comparisons. Repeated MoCA testing may also be affected by practice effects.
Unadjusted HRV changes also favored taVNS. The median change in the standard deviation of normal-to-normal intervals (SDNN) was 6.11 ms versus 2.33 ms (P = 0.006); the root mean square of successive differences between normal-to-normal intervals (RMSSD) was 4.99 ms versus 2.06 ms (P = 0.016); and the low-frequency/high-frequency power ratio (LF/HF) was −0.43 versus −0.16 (P < 0.001). However, in Table 6 of the original article, the direction of the adjusted RMSSD difference and the magnitude of the adjusted LF/HF difference are inconsistent with the within-group changes reported in the same table.


Figure 3 Cognitive Anhedonia and Heart Rate Variability Outcomes
In the upper panel, blue represents the escitalopram group and green represents the taVNS group. The simple between-group P values at week 8 shown in the figure are not the same statistics as the baseline-adjusted analyses of covariance reported in the text. The lower table is reproduced unchanged; as noted above, the adjusted between-group differences for RMSSD and LF/HF are internally inconsistent, so statistical significance alone should not be used to infer a mechanism.
During the 8-week period, nausea or gastrointestinal discomfort, somnolence or daytime fatigue, and dry mouth occurred in 18.33%, 14.17%, and 11.67% of the escitalopram group, respectively, compared with 3.33%, 2.50%, and 1.67% of the taVNS group. In contrast, local ear-skin redness or stinging occurred in 13.33% of the taVNS group and in none of the escitalopram group. All of these differences were statistically significant.
Serious adverse events, suicidal behavior or attempts, and treatment-emergent mania did not differ significantly between groups. However, the event counts were small and do not establish that the risks were equivalent. The electronic medical records did not systematically grade adverse-event severity. In addition, the ear was inspected after every taVNS session, so local reactions may have been more readily detected than adverse effects in the medication group.
Figure 4 Adverse Events
Local ear-skin redness or stinging predominated in the taVNS group, whereas the escitalopram group reported more nausea or gastrointestinal discomfort, somnolence or daytime fatigue, and dry mouth. The table describes records from patients who completed 8 weeks of treatment and does not represent discontinuation or tolerability among all patients who started treatment.

Mechanistic Discussion:Observations and Inferences


The authors proposed that taVNS may regulate sleep-wake networks through the vagal afferent-NTS pathway, influence attention and working memory through the locus coeruleus-norepinephrine system, and contribute to improvement in anhedonia through midbrain reward pathways. Although previous research supports these explanations, the present study did not collect neuroimaging, neurotransmitter, or inflammatory measures and did not manipulate these pathways. It therefore cannot establish a specific mechanism.
HRV provides a physiological window into autonomic change, but it is not direct evidence that a vagal mechanism has been established. The study used only a 5-minute resting measurement at a fixed time of day. Rhythm classification relied on automated device detection rather than independent electrocardiographic interpretation, and all patients were included in the HRV analysis without additional rhythm-based exclusions. Together with the internal numerical issues in Table 6, the HRV findings should be treated as exploratory signals requiring confirmation.
The study's principal limitations arise from its design: it was single-center, retrospective, nonrandomized, and unblinded. Treatment selection was influenced by patient preference, previous treatment experience, device availability, and cost. The analysis included only patients who completed treatment and follow-up and did not report all interim discontinuations. Residual confounding may therefore explain some differences despite propensity score matching. Eight weeks of observation is also insufficient to determine whether benefits persist, whether relapse occurs after treatment stops, or how safe the interventions are over the long term.

Future Directions:Randomized Validation

The next step should be a multicenter, preregistered randomized trial with a sham-stimulation or active-medication control. Blinded assessment and intention-to-treat analysis should be used to test the main findings, and the protocol should prespecify the priority of sleep, cognition, anhedonia, and HRV outcomes together with the approach to multiplicity adjustment. Discontinuation, adherence, and adverse-event severity should be documented, and follow-up should be extended to determine whether benefits persist and whether effect sizes reach a clinically important difference that patients can perceive. Objective sleep monitoring, standardized electrocardiographic interpretation, and neuroimaging or biomarker measures could also be incorporated to test whether physiological changes truly mediate clinical improvement and to compare stimulation doses and identify patients most likely to benefit.

References

Wu, Y.-L., Ding, L., Yu, C.-Y., et al. (2026). Comparative effectiveness of transcutaneous auricular vagus nerve stimulation and escitalopram for depressive symptoms in major depressive disorder. BMC Psychiatry. Article in Press. https://doi.org/10.1186/s12888-026-08785-5

 

Related Posts

穿戴裝置測量的 HRV 準確嗎?這些數值真正代表什麼

穿戴裝置測量心率變異性的準確度,通常足以用來追蹤個人趨勢,尤其是在安靜休息或睡眠期間。但 HRV 數值測得準確,並不代表它能自動準確評估恢復、壓力或健康狀態。答案取決於裝置、計算方式、記錄條件,以及你希望這個數字告訴你什麼。 一枚戒指顯示 35 毫秒,一支手錶顯示 55 毫秒,可能是因為它們使用不同的 HRV 定義。單靠其中任何一個數值,都無法判斷你的迷走神經是否「強壯」、你是否患有長新冠,或一次放鬆練習是否有效。因此,了解穿戴裝置的 HRV 準確度,需要問兩個問題:訊號是否測量得準確?對數值的解讀是否有根據? 什麼是 HRV?研究人員如何計算? 心率變異性(heart rate variability,簡稱 HRV)描述連續心跳之間時間間隔的變化。平均每分鐘跳動 60 次的心臟,不一定剛好每秒跳一次。這些微小的時間變化,包含心血管調節如何回應呼吸、活動和其他需求的資訊。 在研究中...
發表者 Dr. XIAOJane

什麼是危險過低的 HRV?

兩個人可能醒來時靜息心率相同——比如每分鐘 62 下——身體狀態卻截然不同。其中一個人可能休息得很充分,另一個人卻可能仍受到睡眠不足、高強度訓練、酒精、疾病或壓力的影響。心率呈現的是心臟跳動的速度;HRV 則多提供一層資訊,顯示每次心跳之間的變化。 HRV 測量的是正常心跳之間時間上的微小差異。這些變化會受到呼吸、活動、恢復與自律神經系統等因素影響。 沒有一個 HRV 數值對所有人都算是危險偏低。讀數必須依據所採用的指標、測量方式、你平時的範圍、年齡,以及是否伴隨其他症狀來判讀。 如果你正在問「什麼是危險偏低的 HRV?」,數字本身只是起點。下一步是了解到底測量了什麼,以及該如何判讀結果。 在判定 HRV 危險偏低之前,先確認測量的是什麼 兩個 HRV 數值都可以用毫秒表示,卻未必在回答同一個生理問題。在拿自己的數字與網路上的圖表比較之前,先確認它背後的 HRV 指標、記錄長度、感...
發表者 Dr. XIAOJane

什麼是良好的 HRV?

「我的裝置說我的 HRV 是 40 毫秒——這樣算好嗎?」這是許多人在手錶、戒指或健身手環把心率變異度加進早晨儀表板之後,第一個問的問題。誠實的答案是:40 毫秒對你來說可能完全正常,也可能在今天對你來說異常偏低。只有在你了解裝置測量了什麼、你平時的範圍看起來如何,以及測量前後你的身體發生什麼事之後,這個數字才變得有用。這份指南提供一套實用的判斷方式——而不會把 HRV 變成你健康成績的評分。 HRV 實際上測量什麼 心率變異度,或稱 HRV,指的是連續心跳之間時間上的變動,以毫秒為單位。當心率為每分鐘 60 下時,你的心臟通常不會正好每 1,000 毫秒跳一次。一個間期可能是 960 毫秒,下一個是 1,040 毫秒。HRV 就是把這些細微時間差裡的模式加以總結。 這些逐拍變化受到自律神經系統影響,而自律神經系統會因應呼吸、姿勢、身體活動、溫度、情緒、疾病與恢復需求,持續調整心...
發表者 Dr. XIAOJane

配對迷走神經刺激讓中風復健效益維持兩年

配對式迷走神經刺激能讓中風復健成效維持兩年 (invasive vagus nerve stimulation) 引言 為什麼長期效益很重要 一個人是否能再次穩穩地端起杯子,或扣上鈕扣,往往決定了中風後能多獨立地生活。一旦中風進入慢性期,手臂與手部功能的進一步恢復就更加困難。即使復健帶來進步,患者與臨床人員仍想知道這些進步能維持多久。侵入式迷走神經刺激 (invasive vagus nerve stimulation,iVNS) 可以與復健動作同步提供刺激,但它需要手術植入,因此帶來程序負擔與成本等實際障礙。 一篇 2026 年發表於 Neurology 的追蹤研究,檢視了已完成植入式配對刺激治療的慢性缺血性中風患者。研究人員追蹤上肢損傷、活動、參與與生活品質,以判定效益是否持續 2 年;部分參與者也接受了 3 年的評估。核心問題不是治療能否帶來短暫的提升,而是復健成果能否在日常生...
發表者 Dr. XIAOJane

什麼是心率變異性(HRV)?如何正確解讀 HRV

如果你的靜止心率是每分鐘 60 下,哪一種模式聽起來比較健康:一顆像時鐘般精準、每秒跳一次的心臟,還是一顆每次心跳間隔會以毫秒為單位輕微波動的心臟?許多人憑直覺認為心跳越規律越好。但生理學與臨床研究顯示,在正常竇性心律下,健康的心臟並不是節拍器。隨著呼吸、血壓反射與自律神經輸入持續調整心臟的節律,每一次心跳到下一個心跳的間隔會自然波動。這些逐跳波動提供了一扇間接的窗口,讓我們窺見心臟的自律神經調節,包括交感與副交感神經的影響。這種變異稱為心率變異度(heart rate variability),簡稱 HRV。 HRV 較高不一定總是更好,也沒有任何一個「正常」或最佳數值適用於每個人。更有用的做法,是在相似條件下把你的讀值與自己已建立的基準線相比,並著重於長期趨勢,而不是孤立地解讀單一次測量。 什麼是 HRV?它測量什麼? 心率與心率變異度描述的是同一個節律的兩個不同特徵。心率計算你...
發表者 Dr. XIAOJane

迷走神經與消化:神經系統如何控制腸胃功能

同一份午餐,可能今天吃起來很輕鬆,隔天卻讓你脹得不舒服。也許你昨晚沒睡好、在辦公桌前吃飯、匆匆吞下這餐,或是在第一口之前就已經緊繃。食物很重要,但它不是你的消化系統唯一會回應的東西。 你的腸道不斷與大腦交換資訊。迷走神經承擔了其中很大一部分的訊號傳遞,協助協調胃部活動、消化分泌、飽足感、噁心,以及身體如何解讀內在感覺。它是消化的重要一環,但同時也與腸神經系統、荷爾蒙、免疫訊號及其他自律神經一起運作。 迷走神經是什麼?為什麼對消化很重要? 迷走神經的基本解剖 迷走神經是第十對腦神經。它起於腦幹,沿著頸部兩側下行,並在胸腔與腹腔分支。它的纖維延伸到食道、胃、小腸與部分大腸,也到達心臟與肺臟。 它並不是以同樣方式覆蓋整條消化道。迷走神經的輸入在上消化道與近端大腸特別重要。再往下,遠端大腸與直腸更依賴來自下段脊髓的骨盆副交感神經。 這條神經傳向大腦的資訊也比傳離大腦的多。這些傳入纖維會回報...
發表者 ZenoWellTeam

什麼是腸腦連結?如何改善腸腦連結?

同一餐飯連吃兩天,飯後感受可能完全不同。食物相同,但睡眠、壓力、進食速度、荷爾蒙和腸道節律可能不同。這就是日常的腸腦連結:消化與神經系統不斷互相影響。改善通常不是找一種完美益生菌,而是找出讓循環持續的因素。腸腦連結到底是什麼?消化系統有自己的神經、荷爾蒙、免疫細胞、血液供應與微生物群。大腦接收來自腸道的訊息,也會把訊號傳回去。腸腦軸是連結消化道與大腦的雙向網絡,訊息透過神經、荷爾蒙、免疫訊號、血液循環和腸道微生物產物傳遞。為什麼腸道被稱為「第二大腦」?這個稱呼來自腸神經系統,它能在不等待大腦逐步指揮的情況下,協調腸道運動、液體分泌、血流與局部反射。腸道很獨立,但不代表它會自行思考或產生情緒。「腦腸連結」與「腸腦連結」描述的是同一個雙向系統;前者強調壓力如何影響消化,後者強調腸道訊號向上傳遞。更有用的問題是:現在是什麼因素讓循環持續?腸道與大腦如何溝通?迷走神經迷走神經把大量器官感覺訊...
發表者 ZenoWellTeam